363 related articles for article (PubMed ID: 31030806)
21. Novel therapies in β-thalassaemia.
Grech L; Borg K; Borg J
Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiology of beta thalassemia--a guide to molecular therapies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356
[TBL] [Abstract][Full Text] [Related]
23. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
May C; Rivella S; Chadburn A; Sadelain M
Blood; 2002 Mar; 99(6):1902-8. PubMed ID: 11877258
[TBL] [Abstract][Full Text] [Related]
25. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
26. Insight onto the pathophysiology and clinical complications of thalassemia intermedia.
Cappellini MD; Musallam KM; Taher AT
Hemoglobin; 2009; 33 Suppl 1():S145-59. PubMed ID: 20001620
[TBL] [Abstract][Full Text] [Related]
27. How I treat non-transfusion-dependent β-thalassemia.
Saliba AN; Musallam KM; Taher AT
Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
[TBL] [Abstract][Full Text] [Related]
28. [Research progress of iron metabolism in phenotype modification of β-thalassemia].
Chen D; Sun X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253
[TBL] [Abstract][Full Text] [Related]
29. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
Corbacioglu S; Frangoul H; Locatelli F; Hobbs W; Walters M
Am J Hematol; 2024 Mar; 99(3):422-429. PubMed ID: 38100154
[TBL] [Abstract][Full Text] [Related]
30. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies in β-thalassemia: toward a new era in management.
Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
[TBL] [Abstract][Full Text] [Related]
32. Beta-thalassemia.
Galanello R; Origa R
Orphanet J Rare Dis; 2010 May; 5():11. PubMed ID: 20492708
[TBL] [Abstract][Full Text] [Related]
33. Consequences and management of iron overload in sickle cell disease.
Porter J; Garbowski M
Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
[TBL] [Abstract][Full Text] [Related]
34. β-Thalassemia.
Origa R
Genet Med; 2017 Jun; 19(6):609-619. PubMed ID: 27811859
[TBL] [Abstract][Full Text] [Related]
35. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
[TBL] [Abstract][Full Text] [Related]
36. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
[TBL] [Abstract][Full Text] [Related]
38. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
[TBL] [Abstract][Full Text] [Related]
39. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
40. An update on thalassemia intermedia.
Maakaron JE; Cappellini MD; Taher AT
J Med Liban; 2013; 61(3):175-82. PubMed ID: 24422369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
